Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Phase 2 Completed 320 enrolled Vascular Biogenics Ltd. operating as VBL Therapeutics

RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to assess the safety and tolerability of multiple doses of VB-201 administered for 4 weeks and its efficacy on biomarkers.

Timeline

Start: 2010-10
Primary completion: 2011-10
Completion: 2011-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VB-201	Small molecule	—	—

Indications

No indication recorded.